Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Status:
RECRUITING
Trial end date:
2027-01-06
Target enrollment:
Participant gender:
Summary
This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.